Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition

On this episode of Not So Different, we chronicled the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.

Show notes

Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study

https://www.centerforbiosimilars.com/view/eye-on-pharma-formycon-aflibercept-data-sandoz-chmp-nod-henlius-daratumumab-study

Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars

https://www.centerforbiosimilars.com/view/report-over-60-of-providers-plan-to-only-prescribe-interchangeable-adalimumab-biosimilars

IQVIA: US Spending on Biosimilars to Reach $129 Billion Over Next 5 Years

https://www.centerforbiosimilars.com/view/iqvia-us-spending-on-biosimilars-to-reach-129-billion-over-next-5-years

Vizient Report Predicts Over 3% Inflation Rate for Biologics

https://www.centerforbiosimilars.com/view/vizient-report-predicts-over-3-inflation-rate-for-biologics

On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars

https://www.centerforbiosimilars.com/view/on-the-come-up-what-vizient-s-report-says-about-inflation-and-biosimilars

Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations

https://www.centerforbiosimilars.com/view/patients-with-ra-ibd-trust-specialists-biologic-and-biosimilar-recommendations

Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars

https://www.centerforbiosimilars.com/view/study-higher-adherence-rates-among-users-of-the-remicade-vs-infliximab-biosimilars